Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendan P Halloran

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Gastroenterology|December 3, 2015
Recurrent Fevers After Infliximab Therapy for Ulcerative ColitisChristopher Ma, Richard N Fedorak, Brendan P Halloran
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 24, 2012
A pill for cholesterol and a capsule for bleedingBrendan P Halloran, Fred J Stam, Stijn J B Van Weyenberg
World Journal of Gastrointestinal Pathophysiology|November 25, 2015
Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disordersGrace Y Lam, Brendan P Halloran, Anthea C Peters, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 16, 2004
Lesions of T-cell-mediated kidney allograft rejection in mice do not require perforin or granzymes A and BPhilip F Halloran, Joan Urmson, Vido Ramassar, et al.
Journal of Crohn'S & Colitis|June 21, 2014
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort studyChristopher Ma, Vivian Huang, Darryl K Fedorak, et al.
Journal of Clinical Gastroenterology|November 13, 2014
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of ResponseChristopher Ma, Vivian Huang, Darryl K Fedorak, et al.
BMC Medical Informatics and Decision Making|April 2, 2023
A novel smartphone application for the tracking of procedural numbers and trainee experience in gastrointestinal endoscopySergio Zepeda-Gómez, Andrea Dávila-Cervantes, Aldo J Montaño-Loza, et al.
Digestive Diseases and Sciences|November 13, 2020
Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not BeneficialBhairavi Balram, Harshad Joshi, Karen Wong, et al.
Journal of Clinical Gastroenterology|December 24, 2016
Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational StudyLillian Du, Rae Foshaug, Vivian W Huang, et al.
Canadian Journal of Gastroenterology & Hepatology|February 24, 2015
A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levelsVivian Huang, Neil Dhami, Darryl Fedorak, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Gastroenterology|December 3, 2015
Recurrent Fevers After Infliximab Therapy for Ulcerative ColitisChristopher Ma, Richard N Fedorak, Brendan P Halloran
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 24, 2012
A pill for cholesterol and a capsule for bleedingBrendan P Halloran, Fred J Stam, Stijn J B Van Weyenberg
World Journal of Gastrointestinal Pathophysiology|November 25, 2015
Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disordersGrace Y Lam, Brendan P Halloran, Anthea C Peters, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 16, 2004
Lesions of T-cell-mediated kidney allograft rejection in mice do not require perforin or granzymes A and BPhilip F Halloran, Joan Urmson, Vido Ramassar, et al.
Journal of Crohn'S & Colitis|June 21, 2014
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort studyChristopher Ma, Vivian Huang, Darryl K Fedorak, et al.
Journal of Clinical Gastroenterology|November 13, 2014
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of ResponseChristopher Ma, Vivian Huang, Darryl K Fedorak, et al.
BMC Medical Informatics and Decision Making|April 2, 2023
A novel smartphone application for the tracking of procedural numbers and trainee experience in gastrointestinal endoscopySergio Zepeda-Gómez, Andrea Dávila-Cervantes, Aldo J Montaño-Loza, et al.
Digestive Diseases and Sciences|November 13, 2020
Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not BeneficialBhairavi Balram, Harshad Joshi, Karen Wong, et al.
Journal of Clinical Gastroenterology|December 24, 2016
Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational StudyLillian Du, Rae Foshaug, Vivian W Huang, et al.
Canadian Journal of Gastroenterology & Hepatology|February 24, 2015
A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levelsVivian Huang, Neil Dhami, Darryl Fedorak, et al.
Pageof 3